Novel MS drug likely to survive missed endpoint

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

Novel MS drug likely to survive missed endpoint

Postby MSUK » Mon Oct 24, 2011 12:13 am


With one exception, the investigational oral drug laquinimod was more effective than placebo, and possibly better than interferon-beta-1a (Avonex), in reducing clinically relevant aspects of multiple sclerosis (MS), a researcher said here.

But that exception was a doozy: on the phase III BRAVO trial's primary efficacy endpoint, annualized relapse rate, laquinimod failed to show significantly better efficacy than placebo, reported Timothy Vollmer, MD, of the University of Colorado in Denver.

According to the two-year trial's prespecified method for measuring annualized relapse rates in the primary analysis, laquinomid produced a rate of 0.28 relapses, versus 0.34 for placebo (risk ratio 0.82, 95% CI 0.66 to 1.02, P=0.075).

On the other hand, when the data were adjusted for baseline clinical factors associated with relapse rate that were imbalanced between treatment groups in the randomized trial -- also planned in the BRAVO protocol -- annualized relapse rates rose enough in the placebo group to give laquinimod a statistically significant advantage (0.37 placebo, 0.29 laquinimod, P=0.03).... Read More - ... ageid/1735
User avatar
Family Elder
Posts: 2468
Joined: Wed Oct 14, 2009 3:00 pm


Re: Novel MS drug likely to survive missed endpoint

Postby Luongo » Fri Oct 28, 2011 4:41 pm

Its so hard to have any faith in any of these jackals...
User avatar
Family Member
Posts: 51
Joined: Fri Jan 14, 2011 4:00 pm

Return to General Discussion


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service